These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35200071)

  • 1. Geraniin as a potential inhibitor of SARS-CoV-2 3CL
    Yu WD; Jin QY; Zeng MS; Liu JY; Xu PP
    Nat Prod Res; 2022 Dec; 36(23):6060-6063. PubMed ID: 35200071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
    Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
    Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses.
    Wang R; Zhai G; Zhu G; Wang M; Gong X; Zhang W; Ge G; Chen H; Chen L
    Bioorg Chem; 2023 Jan; 130():106264. PubMed ID: 36395603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding and inhibitory effect of ravidasvir on 3CL
    Bera K
    J Biomol Struct Dyn; 2022 Oct; 40(16):7303-7310. PubMed ID: 33682639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations.
    Ahmad B; Batool M; Ain QU; Kim MS; Choi S
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CL
    Eberle RJ; Olivier DS; Amaral MS; Gering I; Willbold D; Arni RK; Coronado MA
    Viruses; 2021 May; 13(5):. PubMed ID: 34068686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL
    Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S
    Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting allosteric pockets of SARS-CoV-2 main protease M
    Bhat ZA; Chitara D; Iqbal J; Sanjeev BS; Madhumalar A
    J Biomol Struct Dyn; 2022 Sep; 40(14):6603-6618. PubMed ID: 33645457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and Biochemical Evaluation of 8
    Wu J; Feng B; Gao LX; Zhang C; Li J; Xiang DJ; Zang Y; Wang WL
    Molecules; 2022 May; 27(10):. PubMed ID: 35630836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL
    Ma L; Xie Y; Zhu M; Yi D; Zhao J; Guo S; Zhang Y; Wang J; Li Q; Wang Y; Cen S
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.
    Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD
    J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses.
    Brier L; Hassan H; Hanoulle X; Landry V; Moschidi D; Desmarets L; Rouillé Y; Dumont J; Herledan A; Warenghem S; Piveteau C; Carré P; Ikherbane S; Cantrelle FX; Dupré E; Dubuisson J; Belouzard S; Leroux F; Deprez B; Charton J
    Eur J Med Chem; 2023 Mar; 250():115186. PubMed ID: 36796300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inhibitory effect of some natural bioactive compounds against SARS-CoV-2 main protease: insights from molecular docking analysis and molecular dynamic simulation.
    Abdelrheem DA; Ahmed SA; Abd El-Mageed HR; Mohamed HS; Rahman AA; Elsayed KNM; Ahmed SA
    J Environ Sci Health A Tox Hazard Subst Environ Eng; 2020; 55(11):1373-1386. PubMed ID: 32998618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL
    Zhang JW; Xiong Y; Wang F; Zhang FM; Yang X; Lin GQ; Tian P; Ge G; Gao D
    Eur J Med Chem; 2022 Jan; 228():114030. PubMed ID: 34883292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of New Hydroxyethylamine Analogs against 3CL
    Kumar S; Sharma PP; Shankar U; Kumar D; Joshi SK; Pena L; Durvasula R; Kumar A; Kempaiah P; Poonam ; Rathi B
    J Chem Inf Model; 2020 Dec; 60(12):5754-5770. PubMed ID: 32551639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening.
    Abian O; Ortega-Alarcon D; Jimenez-Alesanco A; Ceballos-Laita L; Vega S; Reyburn HT; Rizzuti B; Velazquez-Campoy A
    Int J Biol Macromol; 2020 Dec; 164():1693-1703. PubMed ID: 32745548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chetomin, a SARS-CoV-2 3C-like Protease (3CL
    Ibrahim MAA; Abdelrahman AHM; Mohamed DEM; Abdeljawaad KAA; Naeem MA; Gabr GA; Shawky AM; Soliman MES; Sidhom PA; Paré PW; Hegazy MF
    Viruses; 2023 Jan; 15(1):. PubMed ID: 36680290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 3CL
    Kuo CJ; Liang PH
    FEBS Lett; 2022 May; 596(9):1214-1224. PubMed ID: 35302661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.